Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00471341 · ClinicalTrials.gov registry record · Phase 4
Effect of Celecoxib on Markers of Vascular Inflammation
A Phase 4 study of Hypertension and Coronary Artery Disease, sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
- 2
- Study locations
NCT00471341 is a Phase 4 study of Hypertension and Coronary Artery Disease that has completed, run by University of Florida. The registered enrollment target is 75 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT00471341, a Phase 4 study of Hypertension and Coronary Artery Disease, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study involves a drug called celecoxib, which is commonly prescribed for people with arthritis. Arthritis is caused by inflammation of the joints or tissues. Inflammation also occurs in the blood vessels that lead to your heart, and the purpose of this study is to see if celecoxib can reduce the blood vessel inflammation associated with high cholesterol and heart disease.
Conditions Studied
Interventions
- DRUG placebo
- DRUG Celecoxib
Study Locations (2)
Florida
- University of Florida - Gainesville
Texas
- University of Texas Health Science Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2002-07 |
| Est. Completion | 2004-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00471341
The ClinicalTrials.gov registry entry for NCT00471341 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension and Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00471341 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT00471341 about?
NCT00471341 is a clinical study titled "Effect of Celecoxib on Markers of Vascular Inflammation". This study involves a drug called celecoxib, which is commonly prescribed for people with arthritis. Arthritis is caused by inflammation of the joints or tissues. Inflammation also occurs in the blood vessels that lead to your heart, and the purpose of this study is to see if celecoxib can reduce th...
What is the current status of trial NCT00471341?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2002-07. Estimated completion is 2004-12.
What conditions does trial NCT00471341 study?
This clinical trial studies the following conditions: Hypertension and Coronary Artery Disease.
What interventions are being tested in trial NCT00471341?
The interventions under investigation include: placebo (DRUG), Celecoxib (DRUG).
Who is sponsoring clinical trial NCT00471341?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00471341 being conducted?
This trial has 2 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.